A detailed history of Mariner, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 12,274 shares of RLMD stock, worth $34,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,274
Previous 17,219 28.72%
Holding current value
$34,367
Previous $51,000 23.53%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.3 - $4.36 $11,373 - $21,560
-4,945 Reduced 28.72%
12,274 $39,000
Q2 2024

Aug 13, 2024

SELL
$2.93 - $4.94 $19,839 - $33,448
-6,771 Reduced 28.22%
17,219 $51,000
Q1 2024

May 15, 2024

BUY
$3.1 - $6.8 $9,678 - $21,229
3,122 Added 14.96%
23,990 $111,000
Q4 2023

Feb 14, 2024

SELL
$2.45 - $4.22 $5,843 - $10,064
-2,385 Reduced 10.26%
20,868 $86,000
Q3 2023

Nov 13, 2023

SELL
$2.48 - $3.79 $18,870 - $28,838
-7,609 Reduced 24.65%
23,253 $69,000
Q2 2023

Aug 11, 2023

BUY
$2.22 - $3.54 $13,335 - $21,264
6,007 Added 24.17%
30,862 $75,000
Q1 2023

May 12, 2023

SELL
$2.24 - $4.76 $36,344 - $77,231
-16,225 Reduced 39.5%
24,855 $56,000
Q4 2022

Feb 14, 2023

BUY
$2.17 - $35.84 $89,143 - $1.47 Million
41,080 New
41,080 $143,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $80.1M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.